Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.

Literature DB >> 25249654

Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.

Bahar Salavati¹, Tarek K Rajji², Rae Price¹, Yinming Sun³, Ariel Graff-Guerrero⁴, Zafiris J Daskalakis⁵.

Abstract

Cognitive deficits are commonly observed in patients with schizophrenia. Converging lines of evidence suggest that these deficits are associated with impaired long-term potentiation (LTP). In our systematic review, this hypothesis is evaluated using neuroimaging literature focused on proton magnetic resonance spectroscopy, positron emission tomography, and single-photon emission computed tomography. The review provides evidence for abnormal dopaminergic, GABAergic, and glutamatergic neurotransmission in antipsychotic-naive/free patients with schizophrenia compared with healthy controls. The review concludes with a model illustrating how these abnormalities could lead to impaired LTP in patients with schizophrenia and consequently cognitive deficits.

Entities: Disease Species

Keywords: GABA; MRS; PET; SPECT; dopamine; glutamate; long-term potentiation; schizophrenia

Mesh：

Substances：

Year: 2014 PMID： 25249654 PMCID： PMC4266301 DOI： 10.1093/schbul/sbu132

Source DB: PubMed Journal: Schizophr Bull ISSN： 0586-7614 Impact factor: 9.306

148 in total

1. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Authors: Lawrence S Kegeles; Mark Slifstein; Xiaoyan Xu; Nina Urban; Judy L Thompson; Tiffany Moadel; Jill M Harkavy-Friedman; Roberto Gil; Marc Laruelle; Anissa Abi-Dargham
Journal: Biol Psychiatry Date: 2010-07-31 Impact factor: 13.382

2. Glutamine--a major substrate for nerve endings.

Authors: H F Bradford; H K Ward; A J Thomas
Journal: J Neurochem Date: 1978-06 Impact factor: 5.372

3. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.

Authors: Jong H Yoon; Richard J Maddock; Ariel Rokem; Michael A Silver; Michael J Minzenberg; J Daniel Ragland; Cameron S Carter
Journal: J Neurosci Date: 2010-03-10 Impact factor: 6.167

4. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors: Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal: Nature Date: 1997-02-13 Impact factor: 49.962

Review 5. Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

Authors: M Laruelle
Journal: Q J Nucl Med Date: 1998-09

6. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms.

Authors: Kuei Y Tseng; Patricio O'Donnell
Journal: J Neurosci Date: 2004-06-02 Impact factor: 6.167

7. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS.

Authors: Jean Théberge; Yousef Al-Semaan; Peter C Williamson; Ravi S Menon; Richard W J Neufeld; Nagalingam Rajakumar; Betsy Schaefer; Maria Densmore; Dick J Drost
Journal: Am J Psychiatry Date: 2003-12 Impact factor: 18.112

8. Dysfunctional neural plasticity in patients with schizophrenia.

Authors: Zafiris J Daskalakis; Bruce K Christensen; Paul B Fitzgerald; Robert Chen
Journal: Arch Gen Psychiatry Date: 2008-04

9. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study.

Authors: Naoki Goto; Reiji Yoshimura; Junji Moriya; Shingo Kakeda; Nobuhisa Ueda; Atsuko Ikenouchi-Sugita; Wakako Umene-Nakano; Kenji Hayashi; Norihiro Oonari; Yukunori Korogi; Jun Nakamura
Journal: Schizophr Res Date: 2009-05-21 Impact factor: 4.939

10. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia.

Authors: Philip Tibbo; Chris Hanstock; Agitha Valiakalayil; Peter Allen
Journal: Am J Psychiatry Date: 2004-06 Impact factor: 18.112

26 in total

Review 1. Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.

Authors: Trevor Archer; Richard M Kostrzewa
Journal: Neurotox Res Date: 2015-07-15 Impact factor: 3.911

Review 2. Inefficient neural system stabilization: a theory of spontaneous resolutions and recurrent relapses in psychosis

Authors: Lena Palaniyappan
Journal: J Psychiatry Neurosci Date: 2019-11-01 Impact factor: 6.186

3. Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.

Authors: W Gordon Frankle; Jennifer Paris; Michael Himes; N Scott Mason; Chester A Mathis; Rajesh Narendran
Journal: Biol Psychiatry Date: 2017-12-07 Impact factor: 13.382

4. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.

Authors: Dawn E Sugarman; Joao P De Aquino; James Poling; Mehmet Sofuoglu
Journal: Pharmacol Biochem Behav Date: 2019-05-10 Impact factor: 3.533

5. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.

Authors: Fernando Caravaggio; Margaret Hahn; Shinichiro Nakajima; Philip Gerretsen; Gary Remington; Ariel Graff-Guerrero
Journal: Med Hypotheses Date: 2015-06-24 Impact factor: 1.538

Review 6. Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors: Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal: Int Rev Psychiatry Date: 2017-12-08